Last reviewed · How we verify

Effectiveness of Wharton's Jelly-derived Stem Cells in Patients With Osteoarthritis of the Knee, Hip or Glenohumeral Joint and Analysis of the Regeneration Processes Based on Inflammatory Markers, microRNAs and Clinical Features

NCT03866330 Phase 1/Phase 2 UNKNOWN

This phase I/II study will enroll 100 subjects with mild to moderate osteoarthritis of the hip/knee/ glenohumeral joint will be enrolled according to strict inclusion and exclusion criteria. Subjects will receive every three months a single dose of at least 10 million of Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) form the Polish Stem Cell Bank for 12 months (maximum four doses in total and at least 40 million of WJMSC in total) via ultrasound guided intra-articular injection.

Details

Lead sponsorMedical University of Warsaw
PhasePhase 1/Phase 2
StatusUNKNOWN
Enrolment100
Start date2019-03-01
Completion2022-03-01

Conditions

Interventions

Primary outcomes

Countries

Poland